|
Findings show significant progress against HIV epidemic in Africa; 90-90-90 goals in reach
In Zimbabwe, Malawi, and Zambia, new infections are falling; the percent of the population infected with HIV is stabilizing; and over half of all people living with HIV are virally suppressed
Columbia University's Mailman School of Public Health
December 1, 2016 -- NEW YORK - National surveys in Zimbabwe, Malawi, and Zambia reveal exceptional progress against HIV, with decreasing rates of new infection, stable numbers of people living with HIV, and more than half of all those living with HIV showing viral suppression through use of antiretroviral medication. For those on antiretroviral medication, viral suppression is close to 90 percent. Thirty-five years into the global HIV epidemic, these findings are a clear sign of progress and source of hope for the rest of the world.
These data are the first to emerge from the Population HIV Impact Assessment (PHIA) Project, a unique, multi-country initiative funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The Project deploys household surveys, which measure the reach and impact of HIV prevention, care and treatment programs in select countries. ICAP at Columbia University is implementing the PHIA Project in close collaboration with the U.S. Centers for Disease Control and Prevention (CDC) and in partnership with ministries of health.
Importantly, the data positively demonstrate that the 90-90-90 global targets set forth by UNAIDS in 2014 are attainable, even in some of the poorest countries in the world. According to these ambitious targets for 2020, the goal is for 90 percent of people with HIV to be diagnosed, 90 percent of those diagnosed to receive HIV treatment, and 90 percent of those on treatment to be effectively treated and achieve suppression of their infection. This would translate to 73 percent of all HIV-positive people being virally suppressed. The data show that once diagnosed, individuals are accessing treatment, staying on treatment, and their viral load levels are suppressed to levels that maintain their health and dramatically decrease transmission to others.
"The effects of HIV have been far-reaching. But these outcomes affirm that global, country, and U.S.-supported HIV efforts have been successful to date, and that strong progress is being made across the entire HIV continuum of care, including excellent durability of first line treatment regimens with high adherence to medications," said Ambassador Deborah Birx, U.S. Global AIDS Coordinator.
The PHIA Project surveys describe national HIV epidemics by looking at HIV incidence (the rate of new infections), HIV prevalence (the percent of the population living with HIV), and the prevalence of viral load suppression (a measure of a well-controlled HIV infection), all through a nationally-representative sample of the population. Additional measures in the surveys look at the proportion of those with HIV who have been tested and who are on treatment.
The household surveys of approximately 80,000 adults and children in Zimbabwe, Malawi, and Zambia were conducted in 2016. Results show that the rate of new infections is less than one percent per year. HIV prevalence, at 10 to 14 percent, is similar to 2010 estimates, and more than half of all adults living with HIV have viral load suppression. Compared to 2003 incidence estimates for the same three countries of between 1.3 and 1.5 percent per year, the current rate of new HIV infections has been cut in half during the past 13 years, when effective HIV treatment became available in sub-Saharan Africa largely through support from PEPFAR.
"The survey was designed to identify the rate of new infections at the national level, as well as to estimate the number of people living with HIV," said Dr. Jessica Justman, PHIA principal investigator and senior technical director at ICAP. "This information is critically important to determining future resource needs."
Preliminary data analyses show that, as of 2016:
- In Zimbabwe, among adults ages 15 to 64, HIV incidence is 0.45 percent; HIV prevalence is 14.6 percent (16.7 percent among females and 12.4 percent among males); 60.4 percent of all HIV-positive people are virally suppressed, and 86 percent of those on treatment are virally suppressed.
- In Malawi, among adults ages 15 to 64, HIV incidence is 0.37 percent; HIV prevalence is 10.6 percent (12.8 percent among females and 8.2 percent among males); 67.6 percent of all HIV-positive people are virally suppressed, and 91 percent of those on treatment are virally suppressed.
- In Zambia, among adults ages 15 to 59 years, HIV incidence is 0.66 percent; HIV prevalence is 12.3 percent (14.9 percent among females and 9.5 percent among males); 59.8 percent of all HIV-positive people are virally suppressed, and 89 percent of those on treatment are virally suppressed.
"The partnership with the ministries of health has been fundamental to the success of the surveys," said Dr. Shannon Hader, director of the Division of Global HIV and Tuberculosis at CDC. "This kind of information has not been available before and the ministries are eager to use the survey results to inform their policies and programs."
With high HIV prevalence estimates of 10 to14 percent, these three countries continue to bear a substantial HIV burden. Nonetheless, with prevalence stabilizing and incidence falling, the PHIA survey results suggest that people living with HIV are living longer thanks to effective and accessible treatment.
"It is heartening to see the impressive viral suppression noted in the three countries among those on treatment," said Dr. Wafaa El-Sadr, global director of ICAP. "Viral suppression is critical for the well-being of people living with HIV and for preventing HIV transmission to others."
The results from the first three PHIA surveys compel the global community to strengthen its efforts to reach those who have yet to receive an HIV test and to engage, support, and enable those who test HIV-positive to start and stay on effective treatment in order to achieve long-term viral suppression.
"Importantly, the PHIA surveys point to what still needs to be done, who we need to reach, and where we must focus our efforts, in order to build on these achievements," Ambassador Birx added. "The findings will guide an effective response to the epidemic."
###
Detailed data are available in country-specific summary sheets released by the ministry of health in each country and available on the PHIA Project website: phia.icap.columbia.edu.
About the PHIA Project
The PHIA Project is a five-year, multi-country initiative funded by U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC), and conducted by ICAP at Columbia University, CDC, and local governmental and nongovernmental partners. The PHIA Project consists of household-based, population surveys that will collect information related to HIV in 13 countries.
About ICAP
ICAP was founded in 2003 at Columbia University's Mailman School of Public Health. Now a global leader in HIV and health systems strengthening, ICAP provides technical assistance and implementation support to governments and non-governmental organizations in more than 21 countries. ICAP has supported work at more than 5,300 health facilities around the world. More than 2.3 million people have received HIV care through ICAP-supported programs and over 1.3 million have begun antiretroviral therapy. Online at icap.columbia.edu
This project is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement #U2GGH001226. The contents are the responsibility of ICAP and do not necessarily reflect the views of the United States Government.
Columbia University's Mailman School of Public Health
Founded in 1922, Columbia University's Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master's and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.
Media Contact
Stephanie Berger
sb2247@columbia.edu
212-305-4372
@ColumbiaMSPH
http://www. mailman. hs. columbia. edu
Source: https://www.eurekalert.org/pub_releases/2016-12/cums-fss120116.php
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
